Showing 1,268 results

Filters Content type: News, Editors' picks Topic: New & experimental HIV treatments

News and information about clinical trials and regulatory approval of new medications to treat HIV.

New & experimental HIV treatments

How Will Long-Acting HIV Antiretrovirals Work in the Real World?

Editor's pick
The Body Pro
1 August 2018
New & experimental HIV treatments

Doravirine maintains higher rate of virological suppression over darunavir/ritonavir though 96 weeks of follow-up

News
30 July 2018
The search for a cure

The kick that didn’t kill: first-ever randomised HIV cure study fails to eliminate infected cells

News
26 July 2018
Treatment simplification strategies

Dolutegravir dual therapy works well for first-time HIV treatment

News
25 July 2018
New & experimental HIV treatments

The 2018 Pipeline Report

Editor's pick
TAG
24 July 2018
New & experimental HIV treatments

FDA approves Janssen's HIV combination Symtuza

Editor's pick
Pharmaphorum
18 July 2018
Pharmaceutical industry

Gilead's HIV Franchise Under Assault As It Stares Down Paradigm-Changing Drug

Editor's pick
Seeking Alpha
18 July 2018
New & experimental HIV treatments

CytoDyn Announces Positive Results from Completed Pivotal PRO 140 HIV Combination Trial

Editor's pick
CytoDyn press release
17 July 2018
New & experimental HIV treatments

Abivax releases positive top line data from ABX464-005 phase 2a study in HIV infection

Editor's pick
Abivax press release
4 July 2018
New & experimental HIV treatments

European Commission Grants Marketing Authorization for Gilead’s Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for the Treatment of HIV-1 Infection

Editor's pick
Gilead press release
25 June 2018
Vaginal rings & topical PrEP

First Multipurpose Gel Designed to Prevent HIV, HSV, and HPV Simultaneously in Women and Men Advances in Clinical Trials

Editor's pick
Population Council
25 June 2018
Pharmaceutical industry

GSK takes billion-dollar drug fight with Gilead to top AIDS meeting

Editor's pick
Reuters
25 June 2018
New & experimental HIV treatments

GSK's two-drug HIV treatment meets main goal in late stage studies

Editor's pick
Reuters
15 June 2018
How HIV works

ART Simplification Does Not Affect Systemic Inflammation in Virologically Suppressed HIV

Editor's pick
Infectious Disease Advisor
15 June 2018
New & experimental HIV treatments

ViiV Healthcare reports positive results for landmark phase III studies for dolutegravir and lamivudine

Editor's pick
ViiV Healthcare press release
15 June 2018
New & experimental HIV treatments

Single Shot of PRO 140 mAb Cuts HIV Load in Two Thirds on Failing ART

Editor's pick
National AIDS Treatment Advocacy Project
11 June 2018
New & experimental HIV treatments

Is the World Ready for Long-Acting HIV Treatment?

Editor's pick
The Body Pro
11 June 2018
New & experimental HIV treatments

China approves Albuviritide: first domestically developed, long-acting injectable anti-HIV drug

Editor's pick
Firstpost
6 June 2018
Treatment guidelines

Phase 3 registrational data is not sufficient for roll-out of new ARVs in low- and middle-income countries

Editor's pick
HIV i-Base
15 May 2018
Side effects

Is Gilead’s Entire HIV Enterprise Built on a False Promise?

Editor's pick
Poz
10 May 2018
New & experimental HIV treatments

European CHMP Adopts Positive Opinion for Gilead’s Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide)

Editor's pick
Gilead press release
27 April 2018
Side effects

TAF only superior to TDF when used with a boosting agent

News
10 April 2018
Treatment guidelines

U.S. Guidelines Panel Strongly Recommends Gilead’s HIV Regimen Biktarvy

Editor's pick
Poz
4 April 2018
Pharmaceutical industry

A Cheaper Version of Truvada Is Hitting the US Market: Here's Why It Might Not Lower Costs

Editor's pick
The Body
4 April 2018